In our study, the number of phenotypes in the participants with DS and control participants was similar, which may support the hypothesis that polymorphisms influence PON-1 activity; however, this is clearly not responsible for the anti-atherogenic properties of PON-1. Here, PON1 is linked to Dravet syndrome.